Table 3.
Univariable analyses of PFS and OS
| Variables | PFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |
| Age (years) | 0.015* | 0.008** | ||||
| ≤ 65 | Ref. | Ref. | ||||
| >65 | 1.567 | 1.093–2.248 | 1.666 | 1.142–2.429 | ||
| Sex | 0.174 | 0.365 | ||||
| Male | 1.320 | 0.885–1.968 | 1.216 | 0.796–1.859 | ||
| Female | Ref. | Ref. | ||||
| Smoking | 0.391 | 0.717 | ||||
| Never | Ref. | Ref. | ||||
| Ever | 1.168 | 0.819–1.665 | 1.070 | 0.741–1.547 | ||
| ECOG PS | 0.007** | 0.019* | ||||
| 0 | Ref. | Ref. | ||||
| 1 | 1.610 | 1.136–2.283 | 1.548 | 1.073–2.234 | ||
| Lesion type | 0.086 | 0.443 | ||||
| Peripheral | Ref. | Ref. | ||||
| Central | 1.357 | 0.958–1.922 | 1.152 | 0.802–1.655 | ||
| Histological type | 0.835 | 0.816 | ||||
| Adenocarcinoma | Ref. | Ref. | ||||
| Squamous | 1.038 | 0.728–1.482 | 0.957 | 0.661–1.386 | ||
| Clinical stage | 0.017* | 0.045* | ||||
| IIIB | Ref. | Ref. | ||||
| IV | 1.529 | 1.078–2.168 | 1.450 | 1.008–2.086 | ||
| First-line response | < 0.001*** | < 0.001*** | ||||
| CR/PR | Ref. | Ref. | ||||
| SD/PD | 2.725 | 1.905–3.898 | 2.966 | 2.044–4.306 | ||
| CEA | 0.280 | 0.719 | ||||
| Normal | 1.219 | 0.851–1.746 | 1.071 | 0.737–1.557 | ||
| Increased | Ref. | Ref. | ||||
| Albumin | 0.023* | 0.140 | ||||
| Decreased | 1.521 | 1.059–2.183 | 1.323 | 0.913–1.918 | ||
| Normal | Ref. | Ref. | ||||
| WBC | 0.098 | 0.158 | ||||
| ≤ 7.8 | Ref. | Ref. | ||||
| >7.8 | 1.337 | 0.948–1.887 | 1.297 | 0.904–1.860 | ||
| LMR | < 0.001*** | < 0.001*** | ||||
| ≤ 3.73 | 2.373 | 1.643–3.429 | 2.437 | 1.659–3.579 | ||
| >3.73 | Ref. | Ref. | ||||
| NLR | 0.064 | 0.067 | ||||
| ≤ 2.67 | Ref. | Ref. | ||||
| >2.67 | 1.395 | 0.981–1.984 | 1.403 | 0.977–2.017 | ||
| PLR | 0.107 | 0.101 | ||||
| ≤ 164 | Ref. | Ref. | ||||
| >164 | 1.342 | 0.939–1.918 | 1.361 | 0.942–1.968 | ||
| SUVmax | < 0.001*** | < 0.001*** | ||||
| ≤ 11.6 | Ref. | Ref. | ||||
| >11.6 | 2.400 | 1.674–3.440 | 2.976 | 2.024–4.375 | ||
| LMR_SUV | < 0.001*** | < 0.001*** | ||||
| Score 0 | Ref. | Ref. | ||||
| Score 1 | 2.228 | 1.383–3.590 | 0.001** | 2.426 | 1.441–4.085 | 0.001** |
| Score 2 | 4.449 | 2.719–7.281 | < 0.001*** | 5.361 | 3.172–9.058 | < 0.001*** |
PFS progression-free survival, OS overall survival, ECOG PS Eastern Cooperative Oncology Group Performance Status, CR complete response, PR partial response, SD stable disease, PD progressive disease, CEA carcinoembryonic antigen, WBC white blood cell, LMR lymphocyte-monocyte ratio, NLR neutrophil-lymphocyte ratio, PLR platelet-lymphocyte ratio, SUVmax maximum standardized uptake value, HR hazard ratio, CI confidence intervals. *, p < 0.05; **, p < 0.01; ***, p < 0.001